11th February 2012 - New research


Parkinsonism Related Disorders [2012] Feb 6 [Epub ahead of print] (O.Rascol, J.Bronzova, R.A.Hauser, A.E.Lang, C.Sampaio, A.Theeuwes, S.V.van de Witte) Complete abstract

An assessment was made of the efficacy and safety of Pardoprunox in people with Parkinson's Disease who were experiencing motor fluctuations. Pardoprunox is a new partial dopamine agonist being developed that unusually combines two effects as if it were two distinct but combined drugs : partially stimulating dopamine, whose deficiency causes Parkinson's Disease, and fully stimulating serotonin. It was thought that Pardoprunox could avoid some of the severe side effects that other dopamine agonists cause by lessening the effect of dopamine when dopamine activity is high. This study follows on from two previous assessments of Pardoprunox. For more information concerning the earlier studies click here.

Pardoprunox was taken in dosages of up to 42mg per day. Pardoprunox reduced OFF time by 1 hour 37 minutes per day, but even a placebo reduced the OFF time by 55 minutes per day. So the actual benefit of Pardoprunox beyond that of a placebo was a reduction in OFF time of only 42 minutes per day. Pardoprunox made no significant difference to scores on the PDQ-39, which assesses Parkinson's Disease symptoms.  There was a high drop-out rate (37% of people) due to adverse events suggesting that the selected dose range may have been too high, or that the increase in dose may have been too rapid. For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports


2006-2011  Viartis
2015-09-04 03:01:33
[email protected]